Exploratory study to examine the effect of Ramelteon on end of life delirium
Not Applicable
- Conditions
- Advanced cancer
- Registration Number
- JPRN-UMIN000027787
- Lead Sponsor
- Tohoku University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 22
Inclusion Criteria
Not provided
Exclusion Criteria
1. Having regular use of antipsychotics, antidepressants, antimanics and anticonvulsants. 2. Dementia 3. Serious complications such as liver failure, respiratory insufficiency, heart failure, or renal failure 4. Alcoholism or psychiatric patients 5. Already diagnosed delirium 6. Symptomatic intracranial lesions
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Ramelteon's efficacy in managing end-of-life delirium in advanced cancer patients?
How does Ramelteon compare to haloperidol or quetiapine in treating delirium at the end of life for metastatic cancer patients?
Are melatonin receptor expression levels or circadian rhythm biomarkers predictive of Ramelteon response in terminal cancer patients?
What adverse events are associated with Ramelteon use in palliative care settings for advanced cancer patients nearing end-of-life?
What combination therapies or alternative drugs show promise for end-of-life delirium management alongside Ramelteon in oncology?